FountAir From Hong Kong Wins Global Recognition for Breakthrough in Air-to-Water and Cooling Technology
The award is supervised by the UAE Water Aid Foundation (Suqia UAE), under the Mohammed bin Rashid Al Maktoum Global Initiatives. With total prizes of USD 1 million, it promotes the development of innovative, renewable energy-powered technologies to address global water challenges.
Currently in use across six countries, FountAir's AIR4WATER devices use a split air conditioning-water generation system to condense and purify water from the air, while also cooling indoor spaces. The units are compatible with solar or grid power and produce up to 120 litres of safe, mineral-rich drinking water per day. Independent lab testing confirms the water meets WHO quality standards, with a neutral pH level between 6.92 and 7.
The company's two main models – AIR4WATER 400 Pro and AIR4WATER 120 Home – are now deployed in a factory in China, benefitting over 400 individuals in the pilot phase. Additional units are operational in the Philippines, Indonesia, Kenya, Australia, Lebanon and China, offering affordable water at a marginal cost as low as AED 0.009 per litre when connected only to the electricity grid. FountAir's design combines environmental responsibility and user-centric utility.
'The global water crisis stems from the excessive and irresponsible use of technology for comfort. To accelerate solutions, economic incentives must be aligned with technological innovation. This award is a powerful example, as it brings technology and economy together to drive impact. Our solution empowers users to meet their own water needs, sell the excess and scale up the model sustainably. I thank His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, for bridging the gap between those in need and those with the means and will to support lasting change,' said Jannick Jacques Simeray, founder, inventor and CEO at FountAir.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a few seconds ago
- CNBC
Air Canada to restart flights Sunday after Ottawa intervenes in strike
Air Canada says it plans to resume flights on Sunday after the federal government stepped in and ordered binding arbitration to end a flight attendants' strike the day before. The Montreal-based airline says the first flights will resume this evening, but that it will take several days before its operations return to normal. Air Canada says it has been directed by the Canada Industrial Relations Board to resume operations and have flight attendants continue their duties by 2 p.m. ET. The federal government ordered the airline and its flight attendants just yesterday, ending a strike and lockout after less than 12 hours. The Canadian Union of Public Employees, which represents the flight attendants, has accused federal Jobs Minister Patty Hajdu of caving to Air Canada's demands. The Canadian Union of Public Employees, which represents more than 10,000 Air Canada flight attendants, announced its members were heading to the picket lines after being unable to reach an eleventh-hour deal with the airline, while Air Canada locked out its agents about 30 minutes later due to the strike action. This report by The Canadian Press was first published Aug. 17, 2025.
Los Angeles Times
29 minutes ago
- Los Angeles Times
Zero-G Biology
El Segundo-based Varda Space Industries is using space-based technology to manufacture complex pharmaceuticals in orbit, leveraging microgravity to create unique drug formulations for clients. — An El Segundo company has a novel solution to creating complex pharmaceuticals – using space tech to launch them into orbit The next frontier for medicine is closer to Los Angeles than San Francisco but feels like another galaxy. That's because it's about 300 miles straight up above sea level – in low-Earth orbit. Varda Space Industries, an El Segundo microgravity-enabled life sciences company, uses low-Earth orbit to develop unique drug formulations. It's a space-age approach to medicine that launches a capsule containing chemical compounds beyond Earth's atmosphere, where microgravity allows pharmaceutical formulations to be created in a process differently than on the surface. The capsules then reenter the atmosphere with their precious cargo. It became the first company to complete a manufacturing mission conducted outside of the International Space Station last year. Two more missions followed in early 2025 and a fourth launched on June 22. Varda plans to launch one more capsule this year and has four scheduled in 2026, which are all booked to capacity. 'What's special about next year is that the last two capsules will be going up on the same rocket. It will be the first time where we have two spacecraft in orbit at once, and we'll start to move into a fleet mentality,' said Will Bruey, chief executive and co-founder of Varda. Bruey, a former SpaceX engineer co-founded the company in 2021 with Delian Asparouhov, a former principal at Khosla Ventures. The company's growth is supported by a new round of investment. In July, the company announced a $187-million Series C round led by Natural Capital and Shrug Capital, with participation from Founders Fund, Peter Thiel, Khosla Ventures, Caffeinated Capital, Lux Capital and Also Capital. That brings total funding to $329 million. It will use the additional funds to scale operations so that it an expand its capsule production capacity, as well as open additional ground test facilities for pharmaceutical development. Additional capacity could eventually help lower costs – the average mission costs several million dollars today, although the finances are not measured by traditional revenue figures because there is potential to structure deals with royalties from the research and development conducted now. To support its additional manufacturing capabilities, it signed a 10,000-square-foot lease near its El Segundo headquarters for a dedicated lab space that will design molecules and test them prior to launch. The new laboratory will facilitate more complex experiments and allow it to research small molecules and move into more complex biologics. It currently has roughly 130 employees, and that number could increase to 180 within the next 12 months. Bruey envisions a time when there is a steady stream of capsules launching into, and returning from, space for biotech research, with launches on a weekly or daily basis. The company envisions scaling operations by launching more frequently, rather than trying to increase the size of their capsules to accommodate more experiments at a single launch. He likened it to his first job as a pizza delivery driver where the goal was to deliver many pizzas hot and fast to a large number of customers rather than waiting for a large order that required a semitruck to make the delivery. The capsules and satellite buses that carry them are constructed at the company's 61,000-square-foot headquarters where it forges raw materials into space vehicles. Those are then transported to Vandenberg Space Force Base up the coast near Santa Barbara for launch aboard a SpaceX rocket. Reusable rockets have lowered the cost of access to space and opened a range of in-space activities. Increased launch capabilities from companies, such as Long Beach-based Relativity Space, could lower costs even further as the lower-earth-orbit economy becomes more attainable as a destination for manufacturing, biotech, data centers and other technologies. Inside of the Varda capsule, custom-made lab equipment holds raw components that are mixed to form the targeted chemical compound. The device itself is small – measuring less than two feet tall by one foot wide. It has proprietary technology that is different from lab equipment on Earth. For example, a gas bubble that forms during an experiment on Earth would escape due to gravity, but it's not able to do so in space, so the equipment needs to account for environmental factors. Molecules could take a day or more to form, so the capsule remains in space for an extended period of time to complete the experiment. It also must preserve the temperature during re-entry and secure it from vibrations to ensure that the molecule is not destroyed. The capsule re-enters the atmosphere at speeds that reach Mach 25. Re-entry is supervised at the company's mission control center inside the headquarters building, where teams oversee both the capsule re-entry and its novel cargo. The capsule acts like a hypersonic wind tunnel at top speeds, so Varda has secured contracts with NASA and the Department of Defense to test materials for other applications beyond pharmeceutical development. This is also a third line of business – microgravity testing on materials for government and private clients – similar to the way that experiments are conducted on the International Space Station but with full automation and with the results delivered faster and at a lower cost than waiting for transportation to and from the space station. The typical Varda mission can last about two months. Varda is the first and only company to receive a special vehicle operator license under FAA Part 450. The W-4 mission is the first time the agency has issued that license, which allows it to reenter W-series capsules as needed without submitting new safety methodologies to the FAA for each identical flight. It has permission from the FAA to reenter capsules through 2029 before needing to renew the license. The W-4 mission is the maiden flight for Varda's next-generation spacecraft, which includes an in-house platform to navigate the spacecraft during the mission. While in orbit, the satellite bus provides the capsule with power, communications, attitude control and propulsion. When the capsule is ready for re-entry, it separates from the satellite bus and reenters, where it is recovered. Several startups have conducted test flights, such as German firm Atmos Space Cargo, California-based Outpost Space and Inversion Space, but none of these companies have successfully launched and landed a commercial mission. Meanwhile, SpaceX is reportedly interested in developing similar biotech capabilities to Varda. In some ways, the competition has helped Varda by lending validity to its approach to the larger biotech community, which is taking greater interest due to more capacity and competition. 'More people are getting to see the huge opportunity. We're actually pretty excited,' said Bruey. 'We've collaborated with SpaceX the last five years. Our partnership right now is focused on the launch aspect, and we'll continue to collaborate.' In February, Colorado-based Sierra Space, a commercial space and defense company that is building the Dream Chaser spaceplane, announced initiatives to advance research and development of biopharmaceutical solutions in low-Earth orbit during its inaugural mission to the International Space Station. Plans include conducting experiments to identify new ways to deliver cancer therapies to patients on Earth in collaboration with Merck. Another challenge for Varda is companies that are developing commercial space stations, such as Axiom Space, Blue Origin and Starlab Space. While these are in current development, they still have several years before they could come online. 'Once the commercial space stations have real estate in space, they will sell capacity or manufacturing,' said Dr. Leon Alkalai, chief executive at Mandala Space Ventures (and an investor in Varda). However, Varda has a real advantage built in to its ethos. 'Rather than thinking of manufacturing as a service, Varda is making it part of their core competency and betting on the value-add component to make themselves part of the value chain.' Overall, the space economy currently generates $613 billion in revenue, according to a recent report from The Space Foundation, which tracks revenue and spending on space technology. It projects that the space economy could grow to $1 trillion by 2032 at the current growth rate. Asparouhov credited an experiment published by pharmaceutical developer Merck in 2019 regarding the International Space Station as inspiration for Varda. That experiment demonstrated microgravity could develop higher-quality and more uniform crystallization. The applications could lead to new drug formations or entirely new medicines. For example, there is potential for medication that needs to be given intravenously to be recalibrated into a shelf-stable pill format. The company focus is both a biotech formulation platform and a space operation. It doesn't discover the molecules or choose what targets to go after. Rather, its business is to work within the pharmaceutical supply chain during the manufacturing process to open formulations that wouldn't otherwise exist. In a sense, the Varda system is a specialized piece of lab equipment that can introduce a new type of environment for biotech research. Bruey likened it to the introduction of other technologies such as cold and refrigeration, which have major implications on drug development. Crystallization and growth continue on Earth following the initial microgravity development. It's akin to a sourdough starter, which can be expanded to many loaves of bread once it's initially formed. Crystallization processes are commonly used in the manufacture of small molecules and small protein therapeutics. However, it has been challenging to identify the optimal crystallization processes for biologic drugs due to their large size and the flexibility of their structure. Once the drugs are developed, they are still required to go through testing, clinical trials and would need regulatory approval. A traditional drug development timeline could take a decade on average, and Bruey stated that he hopes that Varda's initial microgravity molecules could be available by the end of the decade for commercial use. 'The partners that we have see us as a pharmaceutical company. They don't see us as a space company. They bring us a drug that is having a particular problem, and we go solve it for them and hand it back,' said Asparouhov.
Associated Press
2 hours ago
- Associated Press
Last Chance: Just 7 Days Left to Lock in the LiberNovo Omni Early-Bird Price
HONG KONG / ACCESS Newswire / August 16, 2025 / With only seven days remaining, the LiberNovo Omni Kickstarter campaign is closing in on the finish line, and it's already a record-breaker. With over 8,000 supporters pledging more than $7 million, the Omni has become the highest-funded ergonomic chair in Kickstarter history. The campaign officially ends August 23, 2025, at 8:51 AM PDT (August 23, 11:51 PM CST). When it does, the up to 31% Early-Bird discount will disappear, along with free U.S. shipping (excludes remote and island areas), no VAT or customs fees, and stretch goal rewards. Heard enough? Reserve yours now on Kickstarter Why Omni Is Redefining Ergonomics Omni, the world's first dynamic ergonomic office chair with footrest, is built for people who spend their days creating, coding, designing, gaming, or working remotely and refuse to sacrifice health for productivity. Unlike traditional ergonomic office chairs that are rigid, Omni moves like you do, adjusting in real time to every shift, lean, or stretch. Its Bionic FlexFit backrest uses 16 pivot joints and 8 adaptive panels for seamless, S-curve spinal support. The Dynamic Support system keeps your head, spine, arms, and hips in perfect sync, allowing you to sit naturally, comfortably, and for long hours without compromise, making it one of thebest ergonomic chairs on the market in 2025. Omni also features: Built for People Who Move From all-day design sessions to late-night gaming marathons, Omni is engineered for the way people want to sit, not diagrams of ideal posture. It has the right mode for every part of the day: 105° upright and alert for meetings, 120° slight recline for focused tasking, 135° to kick back and relax, and 160° for a complete reset. Omni adjusts instantly to match your every move. That's why tech reviewers and ergonomics experts alike sing its praise - with Ahnestly naming it the Best Ergonomic Chair of 2025. Early-Bird Backer Rewards All Kickstarter backers get free U.S. shipping (excludes remote and island areas), no VAT or customs fees, and access to stretch goal rewards, including: About LiberNovo Based in Hong Kong, LiberNovo designs products that keep people moving and supported through the most extended workdays. Its flagship ergonomic computer chair Omni dynamic ergonomic chair unites comfort, support, and mobility in one design, helping people work, create, and game without sacrificing their health. Last chance - Early-Bird pricing ends when the Kickstarter campaign closes on August 23. Reserve your LiberNovo Omni now: Kickstarter Campaign Link Contact InformationVicki Qin Integrated Marketing of LiberNovo SOURCE: LiberNovo press release
